Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000986 | 0.92 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL10000993 | 0.87 | TOP1 (0.32) | MEN1KMT2A | |
| SCHEMBL10000997 | 0.86 | MEN1 (0.40) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL10030710 | 0.83 | ADORA2A (0.39) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL10000979 | 0.82 | MEN1 (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL10000992 | 0.82 | MEN1 (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL10001009 | 0.81 | MEN1 (0.32) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL10001006 | 0.81 | ADORA2A (0.32) | MEN1KMT2A | |
| SCHEMBL10001000 | 0.80 | ADK (0.32) | MEN1ALDH1A1KMT2A | |
| SCHEMBL10001007 | 0.80 | ATR (0.31) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475686-B2 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | NOVALED AG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | NOVALED AG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | PNPO, SDHB, PAH | KDM4E 2792/4885MEN1 243/4885ALDH1A1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.